Compare Direxion Daily TSLA Bull 2X Shares (TSLL) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily TSLA Bull 2X Shares vs GeneDx Holdings Corp — how do they compare? Direxion Daily TSLA Bull 2X Shares trades at $10.42 (market cap $3.97B), while GeneDx Holdings Corp trades at $68.16 (market cap $2.02B). The key difference: Direxion Daily TSLA Bull 2X Shares is the larger of the two by market cap, and GeneDx Holdings Corp is more actively traded (734,640 versus 38,458,237). Which is the better fit depends on your goals.
| TSLL | WGS | |
|---|---|---|
Market Cap | $3.97B | $2.02B |
Volume | 38,458,237 | 734,640 |
Sector | Leveraged / Inverse | Health |
52-Week High | $23.03 | $167.51 |
52-Week Low | $6.74 | $34.51 |
Typical Hold Time | — | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TSLL (Direxion Daily TSLA Bull 2X Shares ETF) trades at $10.56, up 4.04% today, with a neutral technical signal overall despite bullish moving averages. The leveraged ETF amplifies Tesla's daily returns, with recent momentum driven by Tesla's Cybercab event anticipation. Key support sits at $10 with resistance at $11, while RSI indicators show mixed signals between short-term overbought conditions and neutral medium-term momentum.
As a leveraged ETF tracking Tesla, TSLL offers amplified exposure but carries significant volatility risks from daily rebalancing effects. The fund's performance remains entirely dependent on Tesla's stock movements, with recent news highlighting both opportunity from Tesla events and the structural risks of holding leveraged products long-term during volatile periods.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
